NO_MORE_FEARProject ID: 664018
H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being
A NOvel FFR Measurement fOR accurate dEtermination of stenosis Functional severity in ischemic hEARt disease
Gesamtkosten:EUR 71 429
EU-Beitrag:EUR 50 000
Thema(en):PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices
Aufruf zur Vorschlagseinreichung:H2020-SMEINST-1-2014See other projects for this call
Finanzierungsprogramm:SME-1 - SME instrument phase 1
Medis medical imaging systems BV (MEDIS), with 25 years of experience in medical imaging, will introduce a novel imaging-based biomarker as an accurate proxy for functional stenosis severity, creating a breakthrough in the treatment of ischemic heart disease (IHD). This non-invasive imaging algorithm should replace the current standard of using a vascular pressure wire to measure the Fractional Flow Reserve (FFR) - a measure for the physiologic significance of a coronary obstruction on the basis of which the interventional cardiologist decides whether an obstruction needs to be treated with stent placement, or otherwise should be left untreated.
Using pressure-wire FFR is risky, time consuming, costly, associated with additional X-ray radiation, not always accurate and not applicable in highly curved arteries. MEDIS has developed a functional prototype of its imaging algorithm (FFRQCA) that accurately calculates the FFR from readily available 2D X-ray images through 3D reconstruction, advanced image processing algorithms and computational fluid dynamics. In a direct comparison with the current standard, this novel approach showed excellent diagnostic accuracy of 88%. Efforts to further optimise the technology are currently ongoing: a multi-centre investigator-driven trial is being carried out across 2 European countries, the US and China.
In this Stage 1 SME Instrument project, MEDIS will investigate the commercial feasibility of this innovation that has already sparked enthusiasm amongst interventional cardiologists worldwide.
EU-Beitrag: EUR 50 000
2316 XG LEIDEN